UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

Moving towards personalized treatments of immune-related adverse events

Nature reviews. Clinical oncology, 2020-08, Vol.17 (8), p.504-515

2020

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era

Arthritis & rheumatology (Hoboken, N.J.), 2022-12, Vol.74 (12), p.1868-1871

2022

Link zum Volltext

Verfügbarkeit prüfen

Breakthrough SARS–CoV‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis

Arthritis & rheumatology (Hoboken, N.J.), 2022-12, Vol.74 (12), p.1906-1915

2022

Link zum Volltext

Verfügbarkeit prüfen

The Future of COVID-19 for Patients With Immune-Mediated Inflammatory Diseases: Who Is at Risk?

Journal of rheumatology, 2024-03, Vol.51 (3), p.221

Calabrese, Cassandra

2024

Link zum Volltext

Verfügbarkeit prüfen

The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management

Rheumatic diseases clinics of North America, 2017-02, Vol.43 (1), p.95

2017

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review

Pathogens & immunity, 2021-05, Vol.6 (1), p.76-103

2021

Link zum Volltext

Verfügbarkeit prüfen

Long COVID: defining the role of rheumatology in care and research

The Lancet. Rheumatology, 2022-12, Vol.4 (12), p.e812-e814

2022

Link zum Volltext

Verfügbarkeit prüfen

The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

Pathogens & immunity, 2021, Vol.6 (1), p.31-54

2021

Link zum Volltext

Verfügbarkeit prüfen

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.1704-1716

2020

Link zum Volltext

Verfügbarkeit prüfen

Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature

Rheumatic & musculoskeletal diseases open, 2019-04, Vol.5 (1), p.e000906-e000906

2019

Link zum Volltext

Verfügbarkeit prüfen

Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

Rheumatic diseases clinics of North America, 2022-05, Vol.48 (2), p.397

Calabrese, Cassandra

2022

Link zum Volltext

Verfügbarkeit prüfen

Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

The Medical clinics of North America, 2021-03, Vol.105 (2), p.213

Calabrese, Cassandra

2021

Link zum Volltext

Verfügbarkeit prüfen

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

Rheumatic & musculoskeletal diseases open, 2022-09, Vol.8 (2), p.e002557

2022

Link zum Volltext

Verfügbarkeit prüfen

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14151-e14151

2019

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Infection-Related Rheumatic Diseases

Frontiers in medicine, 2021-10, Vol.8, p.779773-779773

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series

Cancer medicine (Malden, MA), 2023-02, Vol.12 (3), p.2281-2289

2023

Link zum Volltext

Verfügbarkeit prüfen

Infections in the Era of Targeted Therapies: Mapping the Road Ahead

Frontiers in medicine, 2020-08, Vol.7, p.336-336

2020

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic insights into bone remodelling dysregulation by human viral pathogens

Nature microbiology, 2024-02, Vol.9 (2), p.322

2024

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021

Rheumatic & musculoskeletal diseases open, 2023-08, Vol.9 (3), p.e003250

2023

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 and your rheumatology patients

Cleveland Clinic journal of medicine, 2020-05

Calabrese, Cassandra

2020

Link zum Volltext

Verfügbarkeit prüfen

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study

Cancers, 2023-05, Vol.15 (10), p.2690

2023

Link zum Volltext

Verfügbarkeit prüfen

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors

Cancers, 2023-08, Vol.15 (15), p.4004

2023

Link zum Volltext

Verfügbarkeit prüfen

910 Development and user testing of a website with information for cancer patients who have pre-existing autoimmune disease and are considering immune checkpoint inhibitors (ICIs)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1012-A1012

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(82)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Moving towards personalized treatments of immune-related adverse events

The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era

Breakthrough SARS–CoV‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

The Future of COVID-19 for Patients With Immune-Mediated Inflammatory Diseases: Who Is at Risk?

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management

COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review

Long COVID: defining the role of rheumatology in care and research

The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature

Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)

Editorial: Infection-Related Rheumatic Diseases

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series

Infections in the Era of Targeted Therapies: Mapping the Road Ahead

Mechanistic insights into bone remodelling dysregulation by human viral pathogens

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021

COVID-19 and your rheumatology patients

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors

910 Development and user testing of a website with information for cancer patients who have pre-existing autoimmune disease and are considering immune checkpoint inhibitors (ICIs)

Suchergebnisse filtern